WO2005121121A3 - Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto - Google Patents

Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto Download PDF

Info

Publication number
WO2005121121A3
WO2005121121A3 PCT/US2005/019318 US2005019318W WO2005121121A3 WO 2005121121 A3 WO2005121121 A3 WO 2005121121A3 US 2005019318 W US2005019318 W US 2005019318W WO 2005121121 A3 WO2005121121 A3 WO 2005121121A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulators
metabolism
treatment
substituted aryl
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/019318
Other languages
French (fr)
Other versions
WO2005121121A2 (en
Inventor
Robert M Jones
Graeme Semple
Yifeng Xiong
Young-Jun Shin
Albert S Ren
Juerg Lehmann
Beatriz Fioravanti
Marc A Bruce
Jin Sun Karoline Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE602005011279T priority Critical patent/DE602005011279D1/en
Priority to DK05755596T priority patent/DK1756084T3/en
Priority to AU2005252211A priority patent/AU2005252211A1/en
Priority to US11/628,408 priority patent/US20090036434A1/en
Priority to CA002568451A priority patent/CA2568451A1/en
Priority to RSP-2009/0065A priority patent/RS50755B/en
Priority to EA200602179A priority patent/EA011671B1/en
Priority to PL05755596T priority patent/PL1756084T3/en
Priority to MXPA06014129A priority patent/MXPA06014129A/en
Priority to EP05755596A priority patent/EP1756084B1/en
Priority to HK07104726.6A priority patent/HK1097271B/en
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Priority to BRPI0511757-7A priority patent/BRPI0511757A/en
Priority to NZ552387A priority patent/NZ552387A/en
Priority to HR20090093T priority patent/HRP20090093T3/en
Priority to JP2007515543A priority patent/JP2008501698A/en
Publication of WO2005121121A2 publication Critical patent/WO2005121121A2/en
Publication of WO2005121121A3 publication Critical patent/WO2005121121A3/en
Priority to IL179458A priority patent/IL179458A/en
Anticipated expiration legal-status Critical
Priority to NO20065868A priority patent/NO20065868L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to certain substituted aryl and heteroaryl derivative of Formula (I) that are modulators of metabolism, especially of the activity of a GPCR, referred to herein as RUP3. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.
PCT/US2005/019318 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto Ceased WO2005121121A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
HK07104726.6A HK1097271B (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
AU2005252211A AU2005252211A1 (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US11/628,408 US20090036434A1 (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
CA002568451A CA2568451A1 (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
RSP-2009/0065A RS50755B (en) 2004-06-04 2005-06-02 SUBSTITUTED ARYL AND HETEROARIL DERIVATIVES AS MODULATORS OF METABOLISM AND PROPHYLAXIS AND TREATMENT OF DISEASES RESULTING FROM THIS
EA200602179A EA011671B1 (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
PL05755596T PL1756084T3 (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
MXPA06014129A MXPA06014129A (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto.
BRPI0511757-7A BRPI0511757A (en) 2004-06-04 2005-06-02 substituted aryl and heteroaryl derivatives as metabolism modulators and the prophylaxis and treatment of related disorders
DE602005011279T DE602005011279D1 (en) 2004-06-04 2005-06-02 SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF RELATED DISEASES
DK05755596T DK1756084T3 (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders related thereto
EP05755596A EP1756084B1 (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
NZ552387A NZ552387A (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
HR20090093T HRP20090093T3 (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
JP2007515543A JP2008501698A (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as metabolic regulators and their related diseases prevention and treatment
IL179458A IL179458A (en) 2004-06-04 2006-11-21 Substituted heteroaryl derivatives, pharmaceutical compositions comprising same, method of producing pharmaceutical compositions and use thereof
NO20065868A NO20065868L (en) 2004-06-04 2006-12-19 Substituted aryl and heteroaryl derivatives such as metabolism and prophylaxis modulators and the treatment of disorders associated with this

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57735404P 2004-06-04 2004-06-04
US60/577,354 2004-06-04

Publications (2)

Publication Number Publication Date
WO2005121121A2 WO2005121121A2 (en) 2005-12-22
WO2005121121A3 true WO2005121121A3 (en) 2006-03-16

Family

ID=34971499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/019318 Ceased WO2005121121A2 (en) 2004-06-04 2005-06-02 Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Country Status (30)

Country Link
US (1) US20090036434A1 (en)
EP (1) EP1756084B1 (en)
JP (1) JP2008501698A (en)
CN (2) CN1997640A (en)
AR (1) AR049293A1 (en)
AT (1) ATE415397T1 (en)
AU (1) AU2005252211A1 (en)
BR (1) BRPI0511757A (en)
CA (1) CA2568451A1 (en)
CR (1) CR8741A (en)
CY (1) CY1108762T1 (en)
DE (1) DE602005011279D1 (en)
DK (1) DK1756084T3 (en)
EA (1) EA011671B1 (en)
EC (1) ECSP067066A (en)
ES (1) ES2320359T3 (en)
HR (1) HRP20090093T3 (en)
IL (1) IL179458A (en)
MX (1) MXPA06014129A (en)
NO (1) NO20065868L (en)
NZ (1) NZ552387A (en)
PE (1) PE20060530A1 (en)
PL (1) PL1756084T3 (en)
PT (1) PT1756084E (en)
RS (1) RS50755B (en)
SI (1) SI1756084T1 (en)
TW (1) TW200610528A (en)
UA (1) UA92150C2 (en)
WO (1) WO2005121121A2 (en)
ZA (1) ZA200610095B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470699B2 (en) 2003-07-11 2008-12-30 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8440822B2 (en) 2007-04-18 2013-05-14 Michael Joseph Luzzio Sulfonyl amide derivatives for the treatment of abnormal cell growth
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070091038A (en) * 2004-12-24 2007-09-06 프로시디온 리미티드 Ｇ-protein-coupled receptor (JPP116) agonists and their use to treat obesity and diabetes
DOP2006000008A (en) * 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
EP1902051A1 (en) * 2005-06-09 2008-03-26 Merck Frosst Canada Ltd. Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
AU2006264649A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
BRPI0616245A2 (en) * 2005-09-16 2011-06-14 Arena Pharm Inc metabolism modulator, its uses, a pharmaceutical composition comprising the same as well as a method for producing said composition
NZ571110A (en) * 2006-04-11 2011-03-31 Arena Pharm Inc Methods of using GPR119 receptor to identify Glucose-dependent Insulinotropic Peptide (GIP) secretagogue compounds useful for increasing bone mass in an individual
PE20071221A1 (en) * 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
EP2059517A1 (en) * 2006-08-30 2009-05-20 Biovitrum AB (publ) Pyrimidine compounds for treating gpr119 related disorders
GEP20125425B (en) 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
JP5330260B2 (en) 2006-12-06 2013-10-30 スミスクライン ビーチャム コーポレーション Bicyclic compounds and use as antidiabetics
EP2152707B1 (en) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
PE20090222A1 (en) 2007-05-04 2009-03-27 Bristol Myers Squibb Co [6,6] AND [6,7] -BICYCLIC COMPOUNDS AS AGONISTS OF THE RECEPTOR COUPLED TO PROTEIN G GPR119
PL2170864T3 (en) 2007-07-17 2012-02-29 Bristol Myers Squibb Co Pyridone gpr119 g protein-coupled receptor agonists
ES2499018T3 (en) 2007-09-20 2014-09-26 Irm Llc Compounds and compositions as modulators of the activity of GPR119
KR101536021B1 (en) 2007-10-16 2015-07-10 다이이찌 산쿄 가부시키가이샤 Pyrimidyl indoline compound
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2009063364A2 (en) * 2007-11-13 2009-05-22 Encysive Pharmaceuticals Inc. Modulators of urotensin receptor and methods of use thereof
KR20100120689A (en) * 2008-02-22 2010-11-16 아이알엠 엘엘씨 Compounds and compositions as modulators of gpr119 activity
WO2009129036A1 (en) * 2008-04-14 2009-10-22 Merck & Co., Inc. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2010048149A2 (en) * 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010059384A1 (en) * 2008-10-30 2010-05-27 Janssen Pharmaceutica Nv Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists
EP2382204B1 (en) 2008-12-23 2018-07-11 Merck Sharp & Dohme Corp. Pyrimidine derivatives as gpcr modulators for use in the treatment of obesity and diabetes
AU2009330208A1 (en) 2008-12-23 2011-08-04 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2010085811A2 (en) * 2009-01-26 2010-07-29 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
JP5657518B2 (en) * 2009-02-18 2015-01-21 武田薬品工業株式会社 Fused heterocyclic compounds
CA2754523A1 (en) * 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
WO2010119881A1 (en) * 2009-04-15 2010-10-21 第一三共株式会社 Indoline compound
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011019538A1 (en) 2009-08-13 2011-02-17 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2011061679A1 (en) * 2009-11-23 2011-05-26 Pfizer Inc. Imidazo-pyrazoles as gpr119 inhibitors
EP2528894A1 (en) 2010-01-27 2012-12-05 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
JP2013522279A (en) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination of GPR119 agonist and DDP-IV inhibitor linagliptin for use in the treatment of diabetes and related conditions
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
CN102971311B (en) 2010-05-06 2015-07-08 百时美施贵宝公司 Bicyclic heteroaryl compounds as GPR119 modulators
EP2566862B1 (en) 2010-05-06 2015-09-16 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
AU2011256455A1 (en) 2010-05-17 2013-01-10 Array Biopharma Inc. Piperidinyl-substituted lactams as GPR119 modulators
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
CN103221410B (en) * 2010-09-22 2017-09-15 艾尼纳制药公司 GPR119 receptor modulators and treatment of disorders associated therewith
JO3145B1 (en) 2010-11-08 2017-09-20 Lilly Co Eli Compounds useful for inhibiting chk1
US9000175B2 (en) 2010-11-26 2015-04-07 Lupin Limited Bicyclic GPR119 modulators
KR101913619B1 (en) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Novel compounds as modulators of gpr-119
JP2014520879A (en) 2011-07-15 2014-08-25 ファイザー・インク GPR119 regulator
WO2013066869A1 (en) * 2011-11-03 2013-05-10 Array Biopharma Inc. Piperidinyl-substituted lactams as gpr119 modulators
CN104024246B (en) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 As the substituted pyrimidines derivative of Ou Ruola kinase inhibitor
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
KR102411227B1 (en) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
AR098394A1 (en) * 2013-11-25 2016-05-26 Lilly Co Eli DGAT2 INHIBITORS (DIACILGLICEROL O-ACILTRANSFERASA 2)
MY195016A (en) * 2014-08-04 2023-01-03 Nuevolution As Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (en) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1)
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
WO2017121700A1 (en) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituted 1h-pyrazolo[3,4-b]pyridine derivatives and use thereof as stimulators of soluble guanylate cyclase
CN109890814B (en) 2016-06-09 2023-04-18 普拉马纳制药公司 Compounds comprising benzo [ D ] [1,3] oxathiolane 3-oxides and methods/uses thereof
MX394860B (en) 2016-09-27 2025-03-24 Vertex Pharma Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
JP2020507625A (en) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
MX389800B (en) 2017-02-07 2025-03-20 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
MX392900B (en) 2017-02-07 2025-03-24 Oblique Therapeutics Ab Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer
CA3051644A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Sulfinylpyridines and their use in the treatment of cancer
CN110520124A (en) 2017-02-16 2019-11-29 艾尼纳制药公司 For treating the Compounds and methods for of primary biliary cholangitis
CA3058695A1 (en) 2017-04-26 2018-11-01 Basilea Pharmaceutica International AG Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
US20200129511A1 (en) 2017-06-19 2020-04-30 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of nafld and nash
WO2019104418A1 (en) 2017-11-30 2019-06-06 Pramana Pharmaceuticals Inc. Compounds containing polysubstituted benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide or benzo[d][1,3]oxathiole 3,3-dioxide and methods/uses thereof as agonists of g protein-coupled receptor 119
JP7397011B2 (en) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Methods of treating conditions associated with S1P1 receptors
HRP20231310T1 (en) 2019-05-10 2024-02-02 Deciphera Pharmaceuticals, Llc HETEROARYLAMINOPYRIMIDINE AMIDE INHIBITORS OF AUTOPHAGY AND METHODS OF THEIR APPLICATION
HUE065486T2 (en) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
ES3072710T3 (en) 2019-06-17 2026-07-03 Deciphera Pharmaceuticals Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
BR112022012205A2 (en) * 2019-12-20 2022-09-13 Nuevolution As ACTIVE COMPOUNDS FOR NUCLEAR RECEPTORS
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
JP7713954B2 (en) * 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ Compounds active against nuclear receptors
CA3174252A1 (en) * 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
TW202329937A (en) 2021-12-03 2023-08-01 美商英塞特公司 Bicyclic amine cdk12 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017995A1 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2002045652A2 (en) * 2000-12-04 2002-06-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003000663A1 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. 5-ht receptor ligands and uses thereof
WO2003000687A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
WO2004041164A2 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
WO2004078114A2 (en) * 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
US20050070562A1 (en) * 2003-07-11 2005-03-31 Jones Robert M. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH499528A (en) * 1965-10-22 1970-11-30 Ciba Geigy Ag N,n'-di-(pyrimidyl-(4)-aminoalkyl)-diazacycloalkanes - with antiprotozoal activity
CH480410A (en) * 1967-01-09 1969-10-31 Geigy Ag J R Process for the preparation of water-soluble azopyrimidine dyes
CA961052A (en) * 1967-01-12 1975-01-14 Max Schellenbaum N-2-ethylhexyl-n'-aryl ureas and preparation containing them
US3608087A (en) * 1968-06-21 1971-09-21 Merck & Co Inc Feed compositions
US3887329A (en) * 1969-05-05 1975-06-03 Ciba Geigy Ag Hexamethyl phosphotriamide-dye compositions
US3686238A (en) * 1970-01-19 1972-08-22 Syntex Corp Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3852434A (en) * 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
US3966744A (en) * 1971-01-11 1976-06-29 Syva Company Spin labeled compounds
US3690834A (en) * 1971-01-11 1972-09-12 Syva Co Ligand determination with spin labeled compounds by receptor displacement
DE2106585A1 (en) * 1971-02-11 1972-08-24 Farbenfabriken Bayer Ag, 5090 Leverkusen Aminothiodiazoles and thiodiazole azo dyes
US3966764A (en) * 1972-07-10 1976-06-29 Syva Company Ligand determination of spin labeled compounds by receptor displacement-amphetamine analogs
US3849420A (en) * 1972-10-20 1974-11-19 Dow Chemical Co Bis-(alkylthio-and alkylsulfonyl)-pentachloroquinolines
CH574206A5 (en) * 1972-11-16 1976-04-15 Ciba Geigy Ag
DE2340569C2 (en) * 1973-08-10 1982-12-02 Bayer Ag, 5090 Leverkusen Azo dyes
AT340933B (en) * 1973-08-20 1978-01-10 Thomae Gmbh Dr K PROCESS FOR THE PRODUCTION OF NEW PYRIMIDE DERIVATIVES AND THEIR ACID ADDITIONAL SALTS
US4101541A (en) * 1973-12-21 1978-07-18 Ciba-Geigy Corporation 3-Cyano-1,2,4-thiadiazolyl-5-czo dyestuffs
FR2306697A1 (en) * 1975-04-10 1976-11-05 Sogeras NEW PYRIMIDINES FOR USE AS ANTIDIABETIC AND HYPOCHOLESTEROLEMANT MEDICINAL PRODUCTS
DE2731264A1 (en) * 1977-07-11 1979-02-01 Boehringer Mannheim Gmbh NEW 1-ACYL-2-CYANAZIRIDINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS
JPS6038696B2 (en) * 1977-12-09 1985-09-02 コニカ株式会社 Silver halide color photographic material
US4242507A (en) * 1978-02-23 1980-12-30 Fujisawa Pharmaceutical Co., Ltd. Sulfonic acid esters
DE2831580C2 (en) * 1978-07-18 1980-09-18 Boehringer Mannheim Gmbh, 6800 Mannheim Method and reagent for the determination of glycerin
DE2906603A1 (en) * 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-SUBSTITUTED AZIRIDINE-2-CARBONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE SUBSTANCES
DOP1981004033A (en) * 1980-12-23 1990-12-29 Ciba Geigy Ag PROCEDURE TO PROTECT CROP PLANTS FROM PHYTOTOXIC ACTION OF HERBICIDES.
DE3334455A1 (en) * 1983-03-04 1984-09-06 Bayer Ag, 5090 Leverkusen GUANIDIN DERIVATIVES
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
DE3601196A1 (en) * 1986-01-17 1987-07-23 Merck Patent Gmbh 1,4-DIHYDROPYRIDINE
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
RU2128996C1 (en) * 1994-09-09 1999-04-20 Ниппон Синяку Ко., Лтд. Heterocyclic derivative and a drug
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US6956047B1 (en) * 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
AR008789A1 (en) * 1996-07-31 2000-02-23 Bayer Corp PIRIDINES AND SUBSTITUTED BIPHENYLS
US6008234A (en) * 1996-09-12 1999-12-28 Berlex Laboratories, Inc. Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
CN1290254A (en) * 1998-02-05 2001-04-04 武田药品工业株式会社 Sulfonamide derivatives process for producing the same and utilization thereof
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6239126B1 (en) * 1998-12-17 2001-05-29 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetra-hydropyridine urea derivatives
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
RS20050532A (en) * 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7083933B1 (en) * 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
US7390907B2 (en) * 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2007522233A (en) * 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド Vanilloid receptor ligands and their use in therapy
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017995A1 (en) * 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2002045652A2 (en) * 2000-12-04 2002-06-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003000663A1 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. 5-ht receptor ligands and uses thereof
WO2003000687A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
WO2004041164A2 (en) * 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
WO2004078114A2 (en) * 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
US20050070562A1 (en) * 2003-07-11 2005-03-31 Jones Robert M. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7470699B2 (en) 2003-07-11 2008-12-30 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8440822B2 (en) 2007-04-18 2013-05-14 Michael Joseph Luzzio Sulfonyl amide derivatives for the treatment of abnormal cell growth
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US9296701B2 (en) 2012-04-24 2016-03-29 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9376448B2 (en) 2012-04-24 2016-06-28 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9592232B2 (en) 2012-04-24 2017-03-14 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US9340557B2 (en) 2013-03-12 2016-05-17 Vertex Pharmaceuticals Incorporated Substituted quinoxaline DNA-PK inhibitors
US9359380B2 (en) 2013-03-12 2016-06-07 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors

Also Published As

Publication number Publication date
CY1108762T1 (en) 2014-04-09
ES2320359T3 (en) 2009-05-21
ATE415397T1 (en) 2008-12-15
NZ552387A (en) 2010-10-29
IL179458A (en) 2011-04-28
PE20060530A1 (en) 2006-06-28
EA011671B1 (en) 2009-04-28
RS50755B (en) 2010-08-31
EP1756084A2 (en) 2007-02-28
HK1097271A1 (en) 2007-06-22
CA2568451A1 (en) 2005-12-22
IL179458A0 (en) 2007-05-15
DE602005011279D1 (en) 2009-01-08
EA200602179A1 (en) 2007-04-27
EP1756084B1 (en) 2008-11-26
PT1756084E (en) 2009-02-17
HRP20090093T3 (en) 2009-03-31
ZA200610095B (en) 2008-05-28
BRPI0511757A (en) 2008-01-08
NO20065868L (en) 2007-02-16
ECSP067066A (en) 2007-01-26
MXPA06014129A (en) 2007-03-07
CR8741A (en) 2007-08-28
TW200610528A (en) 2006-04-01
PL1756084T3 (en) 2009-06-30
DK1756084T3 (en) 2009-03-23
UA92150C2 (en) 2010-10-11
AR049293A1 (en) 2006-07-12
CN101870690A (en) 2010-10-27
JP2008501698A (en) 2008-01-24
AU2005252211A1 (en) 2005-12-22
US20090036434A1 (en) 2009-02-05
WO2005121121A2 (en) 2005-12-22
CN1997640A (en) 2007-07-11
SI1756084T1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
UA92150C2 (en) Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2006083491A3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2004076413A3 (en) Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
WO2005007658A3 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
MY141116A (en) Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2004065380A8 (en) 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2007015017A3 (en) Novel polyquinoline derivatives and the therapeutic use thereof
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
EA200970090A1 (en) METABOLISM MODULATORS AND TREATMENT OF RELATED DISORDERS
WO2007035355A3 (en) Modulators of metabolism and the treatment of disorders related thereto
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2007003962A3 (en) Gpcr agonists
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2007053765A3 (en) Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
UA86943C2 (en) Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
UA92450C2 (en) 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2008061238A3 (en) Processes for production of 4-biphenylyazetidin-2-ones
WO2006131398A3 (en) Inhibitors of soluble adenylate cyclase
WO2008010764A3 (en) A process for the preparation of substituted 2-acetylamino-alkoxyphenyl
EP1731502A4 (en) Novel crystal of triterpene derivative
WO2007079929A3 (en) Substituted tricyclic piperidone derivatives
WO2009005469A3 (en) The use of compounds such as pyridoxal derivatives for the treatment of diabetes or diseases associated with the metabolic syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 3206/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: CR2006-008741

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 1200601886

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 179458

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12006502344

Country of ref document: PH

Ref document number: 06118221

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2568451

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007515543

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006/10095

Country of ref document: ZA

Ref document number: 1020067025410

Country of ref document: KR

Ref document number: 200610095

Country of ref document: ZA

Ref document number: 200580017834.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2005755596

Country of ref document: EP

Ref document number: PA/a/2006/014129

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 200602179

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2005252211

Country of ref document: AU

Ref document number: 552387

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2005252211

Country of ref document: AU

Date of ref document: 20050602

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005252211

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067025410

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005755596

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: CR2006-008741

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 11628408

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0511757

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2009/0065

Country of ref document: RS

WWG Wipo information: grant in national office

Ref document number: CR2006-008741

Country of ref document: CR